Therapeutic management of depression has currently important limitations, and its low
efficacy is reflected in high rates of non-response even after multiple trials of …

Many investigational drugs with antidepressant activity are currently explored in different
phases of clinical research, with indications such as major depressive disorder, treatment …

Emerging evidence has implicated the endogenous opioid system in mediating ketamine's
antidepressant activity in subjects with major depressive disorder. To date, mu opioid …

Background Depressive disorders are common. Many patients with major depression do not
achieve remission with available treatments. Buprenorphine has been raised as a potential …

This paper is the forty-second consecutive installment of the annual anthological review of
research concerning the endogenous opioid system, summarizing articles published during …

Background Numerous reports have suggested that buprenorphine may have
antidepressant effects. Many individuals with depressive disorders don't respond to first-line …

The antidepressant effect of ketamine has been widely acknowledged and the use of one of
its enantiomers, S-ketamine (esketamine), has recently been approved for the clinical …

Background: There is a clear clinical need for a better understanding of the biological
underpinnings of major depressive disorder (MDD), allowing for the development of a …

Major depressive disorder is a highly common disorder, with a lifetime prevalence in the
United States of approximately 21%. Traditional antidepressant treatments are limited by a …

Premature mortality trends in the United States are alarming, and years of life lost are mainly
attributable to substance-related deaths and suicide. Suicide risk is significantly elevated …